Indo-Bangla Pharmaceuticals, a company that makes medicines, is looking to start selling its products overseas to help with some challenges it has been facing. The company has announced exciting plans to export medicines to Afghanistan. This is a big step for them, as Afghanistan will be the first country to receive their products through an export agreement. This new direction is meant to help the company get the foreign money, like US dollars, that it needs to buy important ingredients to make its medicines. The company’s board of directors has already given the green light to a special agreement with a firm in Afghanistan. This Afghan company will be the only one allowed to sell Indo-Bangla Pharmaceuticals’ products in Afghanistan. The official signing of this agreement is expected very soon, and it includes a promise for a minimum order value of $0.15 million for each shipment. This export plan is set to last for at least 15 years, starting from 2025 until 2040, and there’s a chance it could continue even longer. Indo-Bangla Pharmaceuticals has been dealing with some tough times in its business. A main reason for their difficulties has been a problem with their bank, which made it hard for them to get the necessary documents to import raw materials. This situation meant they couldn’t make as many medicines as they wanted, which led to lower sales and financial losses over the past year. By focusing on exports, the company hopes to bring in more foreign currency, which will help them overcome these import challenges and make their financial standing stronger in the long run. The medicines will be dispatched under a system known as “Free on Board (FOB) Chittagong basis.” This indicates that Indo-Bangla Pharmaceuticals will handle all associated costs and risks. involved until the medicines are safely loaded onto a shipping vessel at Chittagong port. From there, the Afghan partner will take over. This careful planning shows the company’s commitment to successfully getting its products to international markets. While there have been some questions raised by the company’s auditor about its long-term stability, and there are still some internal ownership requirements to meet, this new export venture is a clear sign of positive action. By reaching out to international markets, Indo-Bangla Pharmaceuticals is taking a proactive step to secure its future, ensure its factories can keep running, and continue providing important healthcare products. This strategic move could bring stability and growth, showing how companies can adapt and find new opportunities even when faced with difficulties, ultimately strengthening their position in the global pharmaceutical landscape.
